financetom
Business
financetom
/
Business
/
Only Rs 1.7 lakh crore likely from bankruptcy proceedings, says Chidambaram
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Only Rs 1.7 lakh crore likely from bankruptcy proceedings, says Chidambaram
Jun 6, 2018 10:02 PM

With Union Minister Arun Jaitley declaring all those who owed money to the banks have been declared insolvent and removed from their companies under the Insolvency and Bankruptcy Code, Congress leader P Chidamabaram said on Wednesday that only Rs 1.7 lakh crore is expected to be recovered out of Rs 4 lakh crore loans involved in the proceedings.

"Out of Rs 4 lakh crore loans involved in Insolvency & Bankruptcy proceedings, only Rs 1.7 lakh crore is expected to be recovered," Chidambaram said in a tweet.

Congress President Rahul Gandhi had alleged earlier in the day that the Modi government had written off loans worth Rs 2.50 lakh crore of some top industrialists.

Jaitley had responded to Gandhi by stating in an article that the government has not waived of a single rupee due from any industrialist. "Those who owed money to the banks and other creditors have been declared insolvent and removed from their companies by IBC (Insolvency and Bankruptcy Code) enacted by Prime Minister Modi's government. These loans were given largely during the UPA government," he said.

Chidambaram, who made a series of tweets, also took a dig at government over the low growth rate of credit to industry.

"Credit to industry in 2018 grew at a grand rate of 1 per cent ! Yes, 1 per cent!...Banks will need a further Rs 60,000 crore towards recapitalisation," he said.

The former Finance Minister also said that the government's Make in India programme had failed to deliver results in defence production.

"Make in India scheme in defence production has been officially abandoned," he added.

First Published:Jun 7, 2018 7:02 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: BP to Acquire Full Ownership of Brazilian Biofuels Joint Venture
Update: BP to Acquire Full Ownership of Brazilian Biofuels Joint Venture
Jun 20, 2024
08:40 AM EDT, 06/20/2024 (MT Newswires) -- (Adds additional information in third and fourth paragraphs.) BP (BP) has agreed to take full ownership of BP Bunge Bioenergia, its Brazilian biofuels joint venture, acquiring Bunge's (BG) 50% interest, the company said Thursday. The enterprise value of the stake to be acquired is about $1.4 billion, BP said. After the transaction, the...
Amazon, Netflix, Cisco And A Big US Bank: CNBC's 'Final Trades'
Amazon, Netflix, Cisco And A Big US Bank: CNBC's 'Final Trades'
Jun 20, 2024
On CNBC's “Halftime Report Final Trades,” Joshua Brown of Ritholtz Wealth Management said he still likes Amazon.com, Inc ( AMZN ). despite the stock trading lower on Tuesday. A California labor regulator fined Amazon ( AMZN ) $5.9 million for allegedly failing to inform workers of productivity quotas at two of its warehouses. Jenny Van Leeuwen Harrington of Gilman Hill...
Castlelake to buy up to $1.2 billion in consumer loans from Upstart
Castlelake to buy up to $1.2 billion in consumer loans from Upstart
Jun 20, 2024
(Reuters) - Private credit lender Castlelake will buy up to $1.2 billion in consumer installment loans from fintech firm Upstart to expand its foothold in the retail lending space, it said on Thursday. The deal underscores how investment firms are increasingly pushing into businesses that have traditionally been dominated by banks as high interest rates and the fear of defaults...
Jazz Pharmaceuticals Says Phase 2b Trial for Suvecaltamide Misses Primary Endpoint -- Shares Slump Pre-Bell
Jazz Pharmaceuticals Says Phase 2b Trial for Suvecaltamide Misses Primary Endpoint -- Shares Slump Pre-Bell
Jun 20, 2024
08:37 AM EDT, 06/20/2024 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) said Thursday that its investigational therapy suvecaltamide did not meet its primary endpoint in a phase 2b trial evaluating its efficacy and safety in adult patients with essential tremor. The company said Suvecaltamide did not achieve statistical significance in reducing certain tremor characteristics. Jazz said it is waiting...
Copyright 2023-2026 - www.financetom.com All Rights Reserved